机器人肝切除与开腹肝切除治疗肝细胞癌的肿瘤学和手术结局比较
本研究回顾性比较了63例机器人肝切除与177例开腹肝切除肝细胞癌患者的手术和肿瘤学结局。机器人组手术时间更长(296±84 vs. 182±51 min,p=0.032),但住院时间显著更短(6.21±2.06 vs. 8.18±6.99天,p=0.001)。两组R0切除率、并发症率、复发率及生存率差异均无统计学意义。
要点
- 机器人肝切除手术时间显著长于开腹组,但住院时间显著缩短。
- 两组R0切除率、并发症率、复发率及1-3年生存率差异无统计学意义。
- 机器人肝切除在选定患者中是安全可行的,肿瘤学结局与开腹手术相当。
核心结论
- 机器人肝切除在选定肝细胞癌患者中是安全可行的手术方式,其肿瘤学和手术结局与开腹手术相当,且住院时间显著更短。
研究设计与样本
- 回顾性分析2013年6月至2016年7月间63例机器人肝切除和177例开腹肝切除肝细胞癌患者的前瞻性收集数据。
主要发现
- 机器人组手术时间显著长于开腹组(296±84 vs. 182±51 min,p=0.032)。
- 机器人组住院时间显著短于开腹组(6.21±2.06 vs. 8.18±6.99天,p=0.001)。
- 两组术后并发症率(11.1% vs. 15.3%,p=0.418)和R0切除率(93.7% vs. 96%,p=0.56)差异无统计学意义。
- 两组总体复发率(27% vs. 37.3%,p=0.140)差异无统计学意义。
- 两组1、2、3年无病生存率(机器人组77.8%、71.9%、71.9% vs. 开腹组72.5%、64.3%、61.6%,p=0.325)和总生存率(机器人组100%、97.7%、97.7% vs. 开腹组95.4%、92.3%、92.3%,p=0.137)差异均无统计学意义。
临床怎么用
- 对于选定的肝细胞癌患者,机器人肝切除可作为开腹肝切除的替代选择,有助于缩短住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most liver resections are currently performed using an open approach. Robotic hepatectomy has been suggested as a safe and effective approach for hepatocellular carcinoma; however, studies regarding oncological and surgical outcomes are still limited. Accordingly, we performed this study to compare the surgical and oncological outcomes between robotic and open approaches. METHODS: Between June, 2013 and July, 2016, a total of 63 HCC patients undergoing robotic hepatectomy, and 177 patients undergoing open hepatectomy were included in this study to assess the surgical and oncological outcomes after hepatectomy. The data of demographic, clinical features, hepatitis profile, tumor characters, TNM stage, surgical type, pathological outcomes, and postoperative results were collected prospectively and analyzed retrospectively. RESULTS: The demographic and clinical features of patients with HCC in both groups were statistically comparable. The robotic group had longer operative times (296 ± 84 vs. 182 ± 51 min, p = 0.032). The postoperative complications rate was slightly lower in the robotic group (11.1 vs. 15.3%, p = 0.418). The rate of Ro resection was similar in both groups (93.7 vs. 96%, p = 0.56). The length of hospital stay was significantly shorter in the robotic group (6.21 ± 2.06 vs. 8.18 ± 6.99 days, p = 0.001). The overall recurrence rate of HCC was lower in the robotic group (27 vs. 37.3%, p = 0.140). The 1, 2, 3 year disease-free survival rates were 72.5, 64.3, and 61.6%, respectively, for the open group, while they were 77.8, 71.9, and 71.9%, respectively, for the robotic group, (p = 0.325). The 1, 2, 3 year overall survival rates were 95.4, 92.3, and 92.3%, respectively, for the open group, while they were 100, 97.7, and 97.7%, respectively, for the robotic group (p = 0.137). CONCLUSION: Robotic surgery is a safe and feasible procedure for liver resection in selected patients. The oncological and surgical outcomes of robotic hepatectomy were comparable to open surgery. The robotic hepatectomy carried significantly shorter length of hospital stay.
引用
- Wang WH, Kuo KK, Wang SN, et al. Oncological and surgical result of hepatoma after robot surgery. Surg Endosc. 2018. PMID: 29488090. doi:10.1007/s00464-018-6131-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。